UK markets closed

Arbutus Biopharma Corporation (0SGC.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.4450+0.1870 (+8.28%)
At close: 02:51PM BST
Full screen
Previous close2.2580
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range2.4450 - 2.4550
52-week range2.4450 - 2.4550
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)2.24
PE ratio (TTM)N/A
EPS (TTM)-0.7050
Earnings date02 Nov 2022 - 07 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript

    At this time, I would like to welcome everyone to the Arbutus Biopharma 2022 second quarter financial results and corporate update. Good morning, everyone, and thank you for joining our second quarter 2022 financial results and corporate update call. Joining me today from the Arbutus executive team are Bill Collier, president and chief executive officer; David Hastings, chief financial officer; Dr. Gaston Picchio, chief development officer; and Dr.

  • Zacks

    Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates

    Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Zacks

    All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

    Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).